Ketamine One (NEO:MEDI.AQN) Interim CEO Adam Deffett joined Steve Darling from Proactive to bring news its wholly-owned contract research organization, KGK Science has been engaged by a third party to develop a ketamine clinical trial that is being planned to be conducted by a clinic operator within its medical facilities located in Miami, Florida.
Deffett telling this study will be to obtain objective data to support the belief that the proper dosing and administration of intravenous Ketamine treatments can result in neuroplasticity and sustainable relief from depression, with or without PTSD.